CoChat

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer

Open access
Doo, David W., Meza-Perez, Selene, Londoño, Angelina I., Goldsberry, Whitney N., Katre, Ashwini A., Boone, Jonathan D., Moore, Dylana J., Hudson, Cindy T., Betella, Ilaria, McCaw, Tyler R., Gangrade, Abhishek, Bao, Riyue, Luke, Jason J., Yang, Eddy S., Birrer, Michael J., Starenki, Dmytro, Cooper, Sara J., Buchsbaum, Donald J., Norian, Lyse A., Randall, Troy D., Arend, Rebecca C. · 2020 · Therapeutic Advances in Medical Oncology
Cited by 52

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: The Wnt/β-catenin pathway is linked to tumorigenesis in a variety of tumors and promotes T cell exclusion and resistance to checkpoint inhibitors. We sought to determine whether a small molecule inhibitor of this pathway, WNT974, would impair tumor growth, affect gene expression patterns, and improve the immune response in human and murine ovarian cancer models. Methods: Human ovarian cancer cells were treated with WNT974 in vitro. RNAseq libraries were constructed and differences in gene expression patterns between responders and nonresponders were compared to The Cancer Genome Atlas (TCGA). Mice with subcutaneous or intraperitoneal ID8 ovarian cancer tumors were treated with WNT974, paclitaxel, combination, or control. Tumor growth and survival were measured. Flow cytometry and β-TCR repertoire analysis were used to determine the immune response. Results: Gene expression profiling revealed distinct signatures in responders and nonresponders, which strongly correlated with T cell infiltration patterns in the TCGA analysis of ovarian cancer. WNT974 inhibited tumor growth, prevented ascites formation, and prolonged survival in mouse models. WNT974 increased the ratio of CD8+ T cells to T regulatory cells (Tregs) in tumors and enhanced the effector functions of infiltrating CD4+ and CD8+ T cells. Treatment also decreased the expression of inhibitory receptors on CD8+ T cells. Combining WNT974 with paclitaxel further reduced tumor growth, prolonged survival, and expanded the T cell repertoire. Conclusions: These findings suggest that inhibiting the Wnt/β-catenin pathway may have a potent immunomodulatory effect in the treatment of ovarian cancer, particularly when combined with paclitaxel.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1758835920913798

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 52

Metadata

Authors
Doo, D. W., Meza-Perez, S., Londoño, A. I., Goldsberry, W. N., Katre, A. A., Boone, J. D., Moore, D. J., Hudson, C. T., Betella, I., McCaw, T. R., Gangrade, A., Bao, R., Luke, J. J., Yang, E. S., Birrer, M. J., Starenki, D., Cooper, S. J., Buchsbaum, D. J., Norian, L. A., Randall, T. D., & Arend, R. C.
Venue
Therapeutic Advances in Medical Oncology
Published
2020-01
Volume
12
Pages
1758835920913798-1758835920913798
ISSN
  • 1758-8340 (ISSN-L)
  • 1758-8359
OpenAlex
W3016290153
Cited by
52
References
11
FWCI
1.84
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. https://app.cochat.ai/papers/10.1177/1758835920913798
The paper
Doo, D. W., Meza-Perez, S., Londoño, A. I., Goldsberry, W. N., Katre, A. A., Boone, J. D., Moore, D. J., Hudson, C. T., Betella, I., McCaw, T. R., Gangrade, A., Bao, R., Luke, J. J., Yang, E. S., Birrer, M. J., Starenki, D., Cooper, S. J., Buchsbaum, D. J., Norian, L. A., . . . Arend, R. C. (2020). Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758835920913798

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.